Endometrial Cancer Clinical Trial
Official title:
The Role of Hypoxia as a Selective Pressure for TP53 Mutations
The study aims to develop scans that tell the investigators about the oxygen content of
tumours using Magnetic Resonance Imaging (MRI) and seeing whether regions of low oxygen
content are related to mutations in cancer genes such as TP53. MRI is a method of obtaining
pictures of inside of the body that shows the appearance and structure of soft tissues.
To get the information about the oxygen content of tumours, MRI is carried out while
breathing 100% oxygen. The variation of oxygen supply to different regions of the tumour will
help the investigators to predict tumour behavior and tumour response to treatment.
Cancer tissue harbours a multitude of genetic alterations, and it is well-established that
when certain key alterations develop, they are powerful determinants of tumour behaviour
(growth rate, potential to spread). One of the most sinister and well-recognized alterations
is in a gene called TP53. Another feature of tumours that results in resistance to treatment
and poor outcome is a low oxygen level within tumour tissue. However, whether alterations in
TP53 are driven by low oxygen levels is not established.
Endometrial cancer is a good model to study the relationship between low tumour oxygen levels
and alterations in TP53 within tumour. Firstly, it is a common gynaecological malignancy,
(9,300 new cases annually in the UK) with two recognized types based on the appearance and
behaviour of the tumour. In type I (endometrioid and mucinous carcinomas), alterations in
TP53 are uncommon (15%), while in type II (serous and clear cell carcinomas) they are common
(88%). In-line with this, the survival of patients with Type 2 cancer is worse. Secondly,
endometrial cancer is routinely assessed at diagnosis using Magnetic Resonance Imaging. This
non-invasive scanning technique can be manipulated to derive additional information about the
oxygen status of the whole tumour and regions within it. Finally, the primary management of
endometrial cancer is surgical and involves hysterectomy. This means it is possible to obtain
fresh tumour tissue at the time of surgery from regions that have been identified on imaging
as having low vs.high levels of oxygen and to establish their TP53 status. In this study,
therefore, the investigator will establish the regional oxygen distribution within
endometrial cancers at diagnosis, and relate them to the alterations in TP53 from fresh
tissue samples from selected regions using gene sequencing. Understanding how highly
deleterious mutations arise in cancer might provide new avenues for intervention and control.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02549989 -
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
|
Phase 2 |